Skip to ContentSkip to Navigation
Over onsFaculty of Science and EngineeringOnderzoekGRIPPharmacoTherapy, -Epidemiology & -Economics (PTEE)Publications

Publications 2011

Below our publications are listed using several headings. Scientific publications relate to original research, often published internationally, but also in the Dutch language. Professional publications are in Dutch and relate to reviews and expressions of opinions.

Scientific publications international
01. Boonstra G, Grobbee DE, Hak E, Kahn RS, Burger H. Initiation of antipsychotic treatment by general practitioners. a case-control study. J Eval Clin Pract 2011;17:12-7
02. Connolly M. Cross-border reproductive care: market forces in action or market failure? An economic perspective, Reprod Biomed Online 2011;23:817-9
03. Connolly MP, Postma MJ, Crespi S, Andersen AN, Ziebe S. The long-term fiscal impact of funding cuts to Danish public fertility clinics, Reprod Biomed Online 2011;23:830-7
04. Crijns HJ, Straus SM, Gispen-de Wied C, de Jong-van den Berg LTW. Compliance with pregnancy prevention programmes of isotretinoin in Europe: a systematic review. Br J Dermatol 2011;164:238-44
05. Crijns HJ, Jentink J, Garne E, Gispen-de Wied CC, Straus SM, de Jong-van den Berg LT, for the EUROCAT Working Group.
The Distribution of Congenital Anomalies Within the VACTERL Association Among Tumor Necrosis Factor Antagonist-exposed Pregnancies Is Similar to the General Population.
J Rheumatol 2011 Jul 1. [Epub ahead of print]
06. Crijns HJ, Straus SM, de Jong-van den Berg LTW. Oral isotretinoin and pregnancy prevention programs: reply from authors, Br J Dermatol 2011. [Epub ahead of print]
07. de Bock GH, Musters RF, Bos HJ, Schroder CP, Mourits MJ, de Jong-van den Berg LTW. Psychotropic medication during endocrine treatment for breast cancer, Support Care Cancer 2011. [Epub ahead of print]
08. de Boer MK, Wiersma D, Bous J, Sytema S, van der Moolen AE, Wilffert B, Hamamura T, Knegtering H. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study), J Clin Psychopharmacol 2011;31:523-5
09. de Gier JJ. DRUID-Project: Update on Medicines, Schriftenreihe Fahreignung 2011;5:71-5
10. de Jong J, Bos JH, de Vries TW, de Jong-van den Berg LTW. Could adverse reactions of antibiotic drugs in children be detected in a prescription database? Pharmacoepidemiol Drug Saf 2011;20:300-3
11. Dijkstra F, Riphagen-Dalhuisen J, Wijers N, Hak E, Van der Sande MA, Morroy G, Schneeberger PM, Schimmer B, Notermans DW, Van der Hoek W. Antibiotic therapy for acute Q fever in The Netherlands in 2007 and 2008 and its relation to hospitalization, Epidemiol Infect 2011;139:1332-41.
12. Duyvendak M, Naunton M, van Roon EN, Brouwers JRBJ. Doctors' beliefs and knowledge on corticosteroid-induced osteoporosis: identifying barriers to improve prevention. J Clin Pharm Ther 2011;36:356-66
13. Eussen SR, Bouvy ML, Rompelberg CJ, Elst ME, Garssen J, Oosterveld MH, Boer A, Gier JJ, Kranen HJ, Klungel OH. Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy, Pharmacoepidemiol Drug Saf 2011 Jun 7. doi: 10.1002/pds.2168. [Epub ahead of print]
14. Gefenaite G, Munster JM, van Houdt R, Hak E. Effectiveness of the Q fever vaccine: a meta-analysis. Vaccine 2011;29:395-98
15. Hak E. Influenza vaccination in young children, Lancet Infect Dis 2011;11:656; author reply 657-8
16. Harmark L, van Hunsel F, Hak E, van Grootheest K. Monitoring the safety of influenza A (H1N1) vaccine using web-based intensive monitoring. Vaccine 2011;29:1941-7
17. Harmark L, Puijenbroek E, Grootheest K. Longitudinal monitoring of the safety of drugs by using a web-based system: the case of pregabalin, Pharmacoepidemiol Drug Saf 2011;20:591-7
18. Harmark L, van Puijenbroek E, Straus S, van Grootheest K. Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information, Drug Saf 2011;34:221-31
19. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, Boersma C, Thompson D, Larholt KM, Diaz M, Barrett A. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2, Value Health 2011;14:429-37
20. Hopman CE, Riphagen-Dalhuisen J, Looijmans-van den Akker I, Frijstein G, Van der Geest-Blankert AD, Danhof-Pont MB, De Jager HJ, Bos AA, Smeets E, De Vries MJ, Gallee PM, Lenderink AF, Hak E.
Determination of factors required to increase uptake of influenza vaccination among hospital-based healthcare workers. J Hosp Infect 2011;77:327-31
21. Hubben G, Bootsma M, Luteijn M, Glynn D, Bishai D, Bonten M, Postma M. Modelling the Costs and Effects of Selective and Universal Hospital Admission Screening for Methicillin-Resistant Staphylococcus aureus. PLoS One 2011;6:e14783
22. Huisman-Baron M, van der Veen L, Jansen PA, van Roon EN, Brouwers JRBJ, van Marum RJ. Criteria for drug selection in frail elderly persons. Drugs Aging 2011;28:391-402
23. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1, Value Health 2011;14:417-28
24. Jansman FG, Reyners AK, van Roon EN, Smorenburg CH, Helgason HH, le Comte M, Wensveen BM, van den Tweel AM, de Blois M, Kwee W, Kerremans AL, Brouwers JRBJ.
Scientific Institute for Dutch Pharmacists (WINAp), Dutch Society for Medical Oncology (NVMO), Dutch Society of Clinical Pharmacology and Biopharmacy (NVKF&B). Consensus-based evaluation of clinical significance and management of anticancer drug interactions. Clin Ther 2011;33:305-14
25. Jentink J, Zetstra-van der Woude AP, Bos J, de Jong-van den Berg LTW. Evaluation of the representativeness of a Dutch non-malformed control group for the general pregnant population: are these controls useful for EUROCAT? Pharmacoepidemiol Drug Saf 2011;20:1217-23
26. Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh B, van Harten PN, Snieder H, Genetic Risk and Outcome in Psychosis (GROUP) investigators. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients, Psychopharmacology (Berl) 2011. [Epub ahead of print]
27. Lako IM, Taxis K, Bruggeman R, Knegtering H, Burger H, Wiersma D, Slooff CJ. The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. Eur Psychiatry 2011.Epub ahead of print.
28. Lako IM, Bruggeman R, Knegtering H, Wiersma D, Schoevers RA, Slooff CJ, Taxis K. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia, J Affect Disord 2011.
29. Leendertse AJ, Van Den Bemt PM, Poolman JB, Stoker LJ, Egberts AC, Postma MJ. Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. Value Health 2011;14:34-40.
30. Leendertse AJ, de Koning FH, Goudswaard AN, Jonkhoff AR, van den Bogert SC, de Gier JJ, Egberts TC, van den Bemt PM. Preventing hospital admissions by reviewing medication (PHARM) in primary care: design of the cluster randomised, controlled, multi-centre PHARM-study. BMC Health Serv Res. 2011 Jan 7;11:4.
31. Looijmans-van den Akker I, Hulscher ME, Verheij TJ, Riphagen-Dalhuisen J, van Delden JJ, Hak E. How to develop a program to increase influenza vaccine uptake among workers in health care settings? Implement Sci 2011;6:47.
32. Luteijn JM, Hubben GA, Pechlivanoglou P, Bonten MJ, Postma MJ. Diagnostic accuracy of culture-based and PCR-based detection tests for methicillin-resistant Staphylococcus aureus: a meta-analysis.
Clin Microbiol Infect 2011;17:146-54
33. Mookhoek EJ, van de Kerkhof PC, Hovens JE, Brouwers JRBJ, Loonen AJ. Substantial skin disorders in psychiatric illness coincide with diabetes and addiction. J Eur Acad Dermatol Venereol 2011;25:392-97
34. Mookhoek EJ, de Vries WA, Hovens JE, Brouwers JRBJ, Loonen AJ. Risk Factors for Overweight and Diabetes mellitus in Residential Psychiatric Patients, Obes Facts 2011;4:341-5
35. Morgan M, de Jong-van den Berg LTW, Jordan S. Drug safety in pregnancy - monitoring congenital anomalies. J Nurs Manag 2011;19:305-310
36. Munster JM, Leenders AC, Hamilton CJ, Hak E, Aarnoudse JG, Timmer A. Placental histopathology after Coxiella burnetii infection during pregnancy, Placenta 2011
37. Muntinghe FL, Vegter S, Verduijn M, Boeschoten EW, Dekker FW, Navis G, Postma MJ. Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients. Pharmacogenet Genomics 2011;21:417-25
38. Neubert A, Hsia Y, de Jong-van den Berg LTW, Janhsen K, Glaeske G, Furu K, Kieler H, Norgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. Br J Clin Pharmacol 2011 Jun 20. doi: 10.1111/j.1365-2125.2011.04045.x. [Epub ahead of print]
39. Nijenhuis CM, Ter Horst PG, de Jong-van den Berg LTW, Wilffert B. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin reuptake inhibitors and tricyclic antidepressants: Part 1 Literature Review, Br J Clin Pharmacol 2011. doi: 10.1111/j.1365-2125.2011.04075.x. [Epub ahead of print]
40. Nijenhuis CM, Ter Horst PG, van Rein N, Wilffert B, de Jong-van den Berg LTW. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin reuptake inhibitors and tricyclic antidepressants: Part 2 Testing the hypotheses, Br J Clin Pharmacol 2011. doi: 10.1111/j.1365-2125.2011.04081.x. [Epub ahead of print]
41. Pechlivanoglou P, Veen WJ van d, Bos JH, Postma MJ. Analyzing generic and branded substitution patterns in the Netherlands using prescription data. BMC Health Serv Res 2011;11:89.
42. Pechlivanoglou P, de Vries RD, Daenen SM, Postma MJ. Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies: Reviewing the Available Evidence, Pharmacoeconomics 2011 Jun 9. doi: 10.2165/11588370.
43. Postma MJ, Boersma C, Vandijck D, Vegter S, Le HH, Annemans L. Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis, Expert Rev Pharmacoecon Outcomes Res 2011;11:367-9.
44. Postma MJ, Jit M, Rozenbaum MH, Standaert BA, Tu HA, Hutubessy RC. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs; a generic approach applied to various regions in the world, BMC Med 2011;9:84
45. Ravera S, van Rein N, de Gier JJ, de Jong-van den Berg LTW. Road traffic accidents and psychotropic medication use in the Netherlands: A case-control study. Br J Clin Pharmacol 2011. doi: 10.1111/j.1365-2125.2011.03994.x. [Epub ahead of print].
46. Riphagen-Dalhuisen J, Gefenaite G, Hak E. Predictors of seasonal influenza vaccination among healthcare workers in hospitals: a descriptive meta-analysis. Occup Environ Med 2011:[Epub ahead of print].
47. Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2011;10:187-99
48. Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ, Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model, BMC Public Health 2011;11:462
49. Rozenbaum MH, De Vries R, LE HH, Postma MJ. Modeling the impact of extended vaccination strategies on the epidemiology of pertussis. Epidemiol Infect 2011; Nov 24;:1-12
50. Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, Hubben G. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in botswana. Am J Respir Crit Care Med 2011;183:1103-11
51. Schimmel AM, Becker ML, van den Bout T, Taxis K, van den Bemt PM. The impact of type of manual medication cart filling method on the frequency of medication administration errors: A prospective before and after study. Int J Nurs Stud 2011;48:791-7
52. Spijkerman J, van Gils EJ, Veenhoven RH, Hak E, Yzerman EP, van der Ende A, Wijmenga-Monsuur AJ, van den Dobbelsteen GP, Sanders EA. Carriage of Streptococcus pneumoniae 3 Years after Start of Vaccination Program, the Netherlands. Emerg Infect Dis 2011;17:584-91
53. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ, van der Weide J, Wilffert B, Deneer VH, Guchelaar HJ. Pharmacogenetics: from bench to byte--an update of guidelines, Clin Pharmacol Ther 2011;89:662-73
54. Ter Horst PG, van der Linde S, Smit JP, den Boon J, van Lingen RA, Jansman FG, De Jong-van den Berg LTW, Wilffert B. Clomipramine concentration and withdrawal symptoms in ten neonates, Br J Clin Pharmacol 2011.
55. Toh S, Mitchell AA, Anderka M, de Jong-van den Berg LTW, Hernandez-Diaz S, .
National Birth Defects Prevention Study. Antibiotics and oral contraceptive failure - a case-crossover study.
Contraception 2011;83:418-425.
56. Tu HA, Rozenbaum MH, Coyte PC, Li SC, Woerdenbag HJ, Postma MJ. Health economics of rotavirus immunization in Vietnam: Potentials for favorable cost-effectiveness in developing countries, Vaccine 2011. [Epub ahead of print]
57. Tu HA, Woerdenbag HJ, Kane S, Rozenbaum MH, Li SC, Postma MJ. Economic evaluations of rotavirus immunization for developing countries: a review of the literature, Expert Rev Vaccines 2011;10:1037-51
58. Tu HA, Vries R de, Woerdenbag HJ, Li SC, Le HH, Phan TL, Hulst M van, Postma MJ. Cost-effectiveness of hepatitis B immunization in Vietnam: application of affordability curves in decision making. Value in Health (Regional issue)
59. Tu HA, Riewpaiboon A, Woerdenbag HJ, Le HH, Le MD, Phan TL, Postma MJ, Li SC. Cost-of-illness of chronic hepatitis B in Vietnam. Value in Health (Regional issue)
60. Upton D, Taxis K, Dunsavage J, Tames MJ. The evolving role of the pharmacist - how can pharmacists drive medication error prevention? EJHP Practice 2011;16:20-1
61. van Gils EJ, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, Bruin JP, van Alphen L, Sanders EA. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial, PLoS One 2011;6:e20229
62. van Gils EJ, Veenhoven RH, Rodenburg GD, Hak E, Sanders EA. Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial, Vaccine 2011;29:7595-8
63. van Grootheest K, Sachs B, Harrison-Woolrych M, Caduff-Janosa P, van Puijenbroek E. Uterine perforation with the levonorgestrel-releasing intrauterine device: analysis of reports from four national pharmacovigilance centres, Drug Saf 2011;34:83-8
64. van Hunsel F, Talsma A, van Puijenbroek E, de Jong-van den Berg L, van Grootheest K.
The proportion of patient reports of suspected ADRs to signal detection in the Netherlands: case-control study.
Pharmacoepidemiol Drug Saf 2011;20:286-91
65. Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LTW, Postma MJ, Boersma C. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs, Am J Manag Care 2011;17:609-16
66. Vegter S, Tolley K, Keith MS, Postma MJ. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis, Value Health 2011;14:852-8
67. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P. Sodium Intake, ACE Inhibition, and Progression to ESRD. J Am Soc Nephrol 2011; Dec 1;
68. Vehof J, Al Hadithy AFY, Burger H, Snieder H, Risselada AJ, Wilffert B, Cohen D, Arends J, Wiersma D, Mulder H, Bruggeman R. Association between the ROBO1 gene and body mass index in patients using antipsychotics. Psychiatr Genet 2011;21:202-7
69. Vehof J, Risselada AJ, Al Hadithy AF, Burger H, Snieder H, Wilffert B, Arends J, Wunderink L, Knegtering H, Wiersma D, Cohen D, Mulder H, Bruggeman R. Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication. Psychopharmacology (Berl) 2011;216:257-65
70. Venmans LM, Gorter KJ, Hak E, Grypdonck MH, de Bruijn O, Rutten GE. Management of infections in type 2 diabetes from the patient's perspective: a qualitative approach. Prim Care Diabetes 2011;5:33-7
71. Vu DH, Koster RA, Alffenaar JW, Brouwers JRBJ, Uges DR. Determination of moxifloxacin in dried blood spots using LC-MS/MS and the impact of the hematocrit and blood volume. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:1063-70
72. Vu DH, Alffenaar JW, Edelbroek PM, Brouwers JRBJ, Uges DR. Dried Blood Spots: A New Tool For Tuberculosis Treatment Optimization, Curr Pharm Des 2011 ;17(27):2931-9
73. Wang H, Land JA, Bos HJ, Bakker MK, de Jong-van den Berg LTW. Clomiphene citrate utilization in the Netherlands 1998-2007. Hum Reprod 2011;26:1227-31
74. Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ, Wilschut JC. Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses, J Infect Dis 2011;204:377-84
75. Westra TA, Parouty MB, Wilschut JC, Boersma C, Postma MJ. Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis. Value Health 2011;14(8):1173-4.
76. Wilffert B, Altena J, Tijink L, van Gelder MM, de Jong-van den Berg LTW.
Pharmacogenetics of drug-induced birth defects: what is known so far?
Pharmacogenomics 2011;12:547-58
77. Wilffert B, Swen J, Mulder H, Touw D, Maitland-Van der Zee AH, Deneer V, KNMP working group Pharmacogenetics. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics, Int J Clin Pharm 2011;33:3-9
78. Zetstra-van der Woude AP, de Walle HEK, de Jong-van den Berg LTW. Periconceptional Folic Acid Use: Still Room to Improve, Birth Defects Research 2011;94:96-101
Scientific publications national
01. Bijlsma MJ, Bos HJ, de Jong-van den Berg LTWW, Janssen F. Periodepatronen, leeftijdpatronen en cohortpatronen in de prevalentie van benzodiazepinegebruik en statinegebruik: de invloed van veranderde richtlijnen. Pharmaceutisch Weekblad Wetenschappelijk Platform 2011;5:a1140
02. de Jong J, Niehoff ML, de Vries TW, de Jong-van den Berg LTWW. Antibiotica bij jonge kinderen geven in de praktijk bij meer dan 30% problemen, Pharmaceutisch Weekblad Wetenschappelijk Platform 2011;5:16-9
03. van Boven JFM, Hiddink EG, Stuurman-Bieze AGG, Postma MJ, Vegter S. Gestructureerde medicatiebegeleiding om de therapietrouw bij bisfosfonaten te verbeteren biedt kansen voor kosteneffectieve farmaceutische patientenzorg. Pharmaceutisch Weekblad Wetenschappelijk Platform 2011;5:a1132
Professional publications
01. de Gier JJ. Rijden onder invloed van geneesmiddelen. MFM-Tijdschrift over praktijkgerichte farmacotherapie 2011;1:24-8
02. de Jong-van den Berg LTWW, Kolling P. Antipsychotica tijdens de zwangerschap, Geneesmiddelenbulletin 2011;45:37-42
03. de Jong-van den Berg LTWW. Geneesmiddelen en zwangerschap, Tijdschrift voor verloskundigen 2011;36:33-6
04. Gefenaite G, Smit M, Nijman HW, Tami A, Drijfhout IH, Pascal A, Postma MH, Wolters BA, van Delden JJM, Wilschut JC, Hak E. Waarom ging de eerste ronde HPV-vaccinatieprogramma mis? Inzicht vanuit gedragsonderzoek onder Nederlandse ouders, Infectieziekten Bulletin 2011;22:167-9
Book (whole)
01. Loonen AJM, Hovens JE. Handboek Functionele Psychofarmacologie. De Tijdstroom: Utrecht, 2011:462
Book (chapter)
01. Brouwers JRBJBJ. Gastro-intestinale bijwerkingen. In: Loonen AJM, Hovens JE, eds. Handboek Functionele Psychofarmacologie. De Tijdstroom: Utrecht, 2011:433-40
02. Postma MJ, de Wit A, Severens H. Economische evaluatiestudies van publieke gezondheidszorg. In: van Lienden HW, Boot JMD., eds. Economie Van De Volksgezondheid. Zorg Voor Gezondheid = Zorg Voor Welvaart. Van Gorcum: Assen, 2011:216-33
03. Taxis K. Metabole en endocriene bijwerkingen. In: Loonen AJM, Hovens JE, eds. Handboek Functionele Psychofarmacologie. De Tijdstroom: Utrecht, 2011:408-14
04. van Harten P, Wilffert B. Bewegingsstoornissen. In: Loonen AJM, Hovens JE, eds. Handboek Functionele Psychofarmacologie. De Tijdstroom: Utrecht, 2011:393-405
05. Wilffert B, Loonen AJM. Inleiding in lichamelijke bijwerkingen. In: Loonen AJM, Hovens JE, eds. Handboek Functionele Psychofarmacologie. De Tijdstroom: Utrecht, 2011:390-1.
06. Wilffert B, Loonen AJM. Cardiovasculaire bijwerkingen. In: Loonen AJM, Hovens JE, eds. Handboek Functionele Psychofarmacologie. De Tijdstroom: Utrecht, 2011:427-32.
Reports
01. De Gier JJ, Ravera S, Monteiro SP, Alvarez FJ. (2011): Establishment of criteria for a European categorisation system for medicinal drugs and driving. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 4.2.1
02. Hermsen J, van Dijk L, Monteiro SP, de Gier JJ. Campagne "Geneesmiddelen in het verkeer": Nameting onder huisartsen en apothekers. Basiseenheid Farmacotherapie en Farmaceutische Patientenzorg, Rijksuniversiteit Groningen, 2011.
03. Meesmann U, Boets S, De Gier JJ, Monteiro S, Alvarez FJ, Fierro I. (2011): Main DRUID results to be communicated to different target groups. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 7.3.2
04. Monteiro S, De Gier JJ (2011): Guidelines and Professional Standards. Report + CD or DVD with examples of ICT supported protocols for prescribing and dispensing of medicines affecting driving performance, and for informing patients who use other psychoactive substances than medicines. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 7.2.2
05. Touliou K, Margaritis D, Spanidis P, Monteiro S, Ravera S, De Gier JJ, Boets S, Meesmann U, Tant M, Legrand S-A, Van der Linden T, Verstraete A, Fierro I, Gomez-Talegan T, Martin L, Álvarez FJ. (2011): Report on the implementation, evaluation and new technologies of practice guidelines and information materials. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). 6th Framework programme. Deliverable 7.4.2
Laatst gewijzigd:19 april 2016 09:34